BUCHANG PHARMA(SH:603858) Zheng Quan Ri Bao·2025-10-29 23:11Core Viewpoint - The company has announced its third-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented, and has made significant governance changes including the cancellation of the supervisory board and adjustments to the board of directors [8][11][13]. Financial Data - The third-quarter financial report is not audited, and the company has confirmed that the financial data is accurate and complete [3][5]. - The report includes major financial indicators and accounting data, although specific figures are not disclosed in the provided documents [3][4]. Governance Changes - The company has proposed to cancel the supervisory board and adjust the number of directors, which requires shareholder approval [13][16]. - The board has also approved amendments to the company's articles of association and governance rules in light of these changes [16][22]. Shareholder Meeting - A temporary shareholder meeting is scheduled for November 17, 2025, to discuss the proposed governance changes and other matters [63][64]. - The meeting will utilize both in-person and online voting methods to facilitate participation [65][66]. International Expansion - The company plans to sign a distribution and marketing agreement with Helios and Early Morning International for its product Efparepoetin alfa in Vietnam, aiming to enhance its international market presence [47][48]. - This agreement is part of the company's strategy to internationalize its products and improve brand influence [60]. Product Development - The product Efparepoetin alfa is a recombinant fusion protein aimed at treating anemia in chronic kidney disease patients and is currently under development with significant R&D investment [50][51]. - The company has invested approximately 51.24 million yuan in the development of this product as of September 30, 2025 [51].